Manages exogenous obesity. ANDA 40526, held by Sun Pharm Industries. Phentermine Hydrochloride.
As of Nov 16, 2026, ANDA 40526 (Phentermine Hydrochloride), held by Sun Pharm Industries, was first approved by FDA on Oct 23, 2003, with 4 approved supplements and 0 published complete response letters.
Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m 2, or ≥ 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 23, 2003 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phentermine Hydrochloride37.5MG · tablet;oral | Phentermine Hydrochloride | Rx |
| May 31, 2017 | Supplement 18Labeling · Standard review | Approved | None posted |
| Apr 23, 2013 | Supplement 11Manufacturing | Approved | None posted |
| Dec 6, 2012 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 23, 2012 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 23, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters